Pfizer, 23andMe team up to study bowel disease
Pfizer Inc. is teaming up with DNA testing company 23andMe to study the possible genetic underpinnings of inflammatory bowel disease, a hard-to-treat ailment that affects an estimated 1.4 million Americans.
Aug 12, 2014
0
0